Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors

BMC Infectious Diseases

Table 2 The Meta-analysis of the prevalence of comorbidities in COVID-19 cases

Diseases	Pooled prevalence	95% CI	I²	P
Hypertension	0.19	0.16–0.22	93.9	< 0.001
Cardiovascular disease	0.06	0.04–0.07	90.5	< 0.001
Diabetes	0.09	0.08–0.11	88.8	< 0.001
COPD	0.03	0.02–0.04	83.0	< 0.001
Cerebrovascular disease	0.03	0.02–0.05	61.4	0.001
Chronic renal disease	0.02	0.01–0.02	51.5	0.004
Chronic liver diseases	0.03	0.02–0.04	72.5	< 0.001
Malignancy	0.01	0.01–0.02	37.8	0.045

Pooled prevalence and 95% confidence intervals (95% CI) of 8 diseases were presented respectively, together with the result of heterogeneity analysis described as I² and P value. P value for heterogeneity among studies assessed with Cochran’s Q test

ISSN: 1471-2334